Teva, Cephalon Win EU Antitrust OK For $6.8B Tie-Up
The European Commission announced Friday that it had conditionally signed off on Teva Pharmaceutical Industries Ltd.'s $6.8 billion acquisition of Cephalon Inc., after Cephalon agreed to sell its rights to market...To view the full article, register now.
Already a subscriber? Click here to view full article